Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026GlobeNewsWire · Oct 15, 2026
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"GlobeNewsWire · Sep 23, 2026
Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Sees Significant Decline in Short InterestDefense World · Sep 14, 2026
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 10, 2026
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2GlobeNewsWire · Sep 9, 2026
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewsWire · Aug 13, 2026Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.47 | -$0.55 | Miss |
| May 14, 2026 | -$0.44 | -$0.58 | Miss |
| Mar 23, 2026 | -$0.50 | -$0.31 | Beat |
| Nov 13, 2025 | -$0.47 | -$0.45 | Beat |
| Aug 11, 2025 | -$0.36 | -$0.66 | Miss |
| May 8, 2025 | -$0.62 | -$0.49 | Beat |